HepaHope, Inc.
HepaHope, Inc. enters into cooperation agreement with Cancer Center of the U.S. National Cancer Institute
HepaHope, Inc. / Alliance 04.09.2009 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- HepaHope, Inc. enters into cooperation agreement with Cancer Center of the U.S. National Cancer Institute - Beckman Research Institute of the City of Hope to supply HepaHope, Inc. with human tissue samples for chemotherapeutic sensitivity testing Irvine (California, USA), September 4, 2009 - HepaHope, Inc. (symbols: 0HH1 and A0RMY), a leading innovator in the use of Organ Slice Cultivation Technology, announced today that it has signed an agreement with the Beckman Research Institute of the City of Hope, located in Duarte, California, to perform analysis of various malignant tumor tissue samples using the Company's proprietary chemosensitivity device. The City of Hope Medical Center is one of the National Cancer Institute-designated Cancer Centers in the U.S. HepaHope's chemosensitivity device uses the Company's proprietary Organ Slice Cultivation Technology to analyze tissue samples and determine a patient's sensitivity to therapeutic agents prior to the administration of chemotherapeutic cancer therapies on such patient. Under the Agreement with the Beckman Research Institute of the City of Hope, HepaHope will evaluate its chemosensitivity device's ability to identify a patient's resistance to multidrug or certain chemotherapeutic regimens. 'Early detection or prediction of resistance to agents is an important factor in choosing the right combination of drugs to set up an effective therapeutic strategy for patients. Patient-specific testing is a new trend in medical diagnostics and we believe our technology is well suited for this interesting market opportunity,' said Dr. Sung-Soo Park, Founder and CEO of HepaHope, Inc. The supply agreement came into effect at the end of August 2009. Testing at HepaHope's research facilities in Irvine, California, is scheduled to start immediately after IRB approval of the City of Hope Medical Center. Disclaimer: Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties. HepaHope disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. About HepaHope: HepaHope, Inc. is a biopharmaceutical company focused on research, development and commercialization of biologic products designed to address the needs of patients with liver failure. The Company's leading proprietary technology, the HepaPheresis(TM) System, is based on an Organ Slice Cultivation Technology which aims to maintain the functionality of various organs out of the body (ex vivo) in order to better support liver failure patients. The HepaPheresis(TM) System is currently being prepared for Phase I clinical trials. HepaHope's patented core technology for organ slice cultivation is also the foundation of other product candidates in the pipeline of this company in the oncology testing market and the drug development market. The members of the management and science advisory board of the company represent leading scientists in liver research. HepaHope was founded in February 1999. The offices and research facilities of the US Company are both located in California. For further information please visit: www.hepahope.com HepaHope, Inc. Bhavesh Singh Chief Financial Officer P + 1 949 421 3617 M + 1 201 920 1819 Investor Relations IR.on AG Achim Josten Dariusch Manssuri T +49 221. 9140.970 F +49 221. 9140.978 E-mail: info@ir-on.com 04.09.2009 Financial News transmitted by DGAP --------------------------------------------------------------------------- Language: English Company: HepaHope, Inc. 30 Fairbanks, Suite 110 CA 92618 Irvin Vereinigte Staaten von Amerika Phone: 001 9494213600 Fax: 001 9494213680 E-mail: investor@hepahope.com Internet: http://www.hepahope.com ISIN: US42689N1090, USU425541021 WKN: A0RMY4, A0RLC1 Listed: Freiverkehr in Düsseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden